BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 9513575)

  • 1. [Diabetes and hyperglycemia in patients under treatment for HIV infection with the protease inhibitors indavir, ritonavir, saquinavir as well as nelfinavir (in development, but not yet released].
    Pharm Unserer Zeit; 1997 Dec; 26(6):317. PubMed ID: 9513575
    [No Abstract]   [Full Text] [Related]  

  • 2. The effects of antiretroviral protease inhibitors on serum lipid levels in HIV-infected patients.
    Chang ES; Tetreault DD; Liu YT; Beall GN
    J Am Diet Assoc; 2001 Jun; 101(6):687-9. PubMed ID: 11424549
    [No Abstract]   [Full Text] [Related]  

  • 3. Hyperlipidemia associated with the use of protease inhibitors.
    Smith JH; Martin GJ; Decker CF
    Clin Infect Dis; 2000 Jul; 31(1):207-8. PubMed ID: 10913432
    [No Abstract]   [Full Text] [Related]  

  • 4. Type 2 diabetes in association with HIV-1 protease inhibitors in HIV-infected patients.
    Chronister CL; Gurwood AS
    J Am Optom Assoc; 1998 Nov; 69(11):695-8. PubMed ID: 9844321
    [No Abstract]   [Full Text] [Related]  

  • 5. The choice of HIV protease inhibitor: indinavir is currently the best option.
    Prescrire Int; 1999 Apr; 8(40):55-60. PubMed ID: 10848067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A patient's guide to protease inhibitors.
    Elperin A; Sax P
    AIDS Clin Care; 1996 Oct; 8(10):83-4. PubMed ID: 11363988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study.
    Baldini F; Di Giambenedetto S; Cingolani A; Murri R; Ammassari A; De Luca A
    AIDS; 2000 Jul; 14(11):1660-2. PubMed ID: 10983656
    [No Abstract]   [Full Text] [Related]  

  • 8. The safety and antiviral effect of protease inhibitors in children.
    Temple ME; Koranyi KI; Nahata MC
    Pharmacotherapy; 2001 Mar; 21(3):287-94. PubMed ID: 11253853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of protease inhibitors on the sense of taste.
    Schiffman SS; Zervakis J; Heffron S; Heald AE
    Nutrition; 1999 Oct; 15(10):767-72. PubMed ID: 10501290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications.
    Kaul DR; Cinti SK; Carver PL; Kazanjian PH
    Pharmacotherapy; 1999 Mar; 19(3):281-98. PubMed ID: 10221367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.
    Périard D; Telenti A; Sudre P; Cheseaux JJ; Halfon P; Reymond MJ; Marcovina SM; Glauser MP; Nicod P; Darioli R; Mooser V
    Circulation; 1999 Aug; 100(7):700-5. PubMed ID: 10449690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.
    Carr A; Samaras K; Burton S; Law M; Freund J; Chisholm DJ; Cooper DA
    AIDS; 1998 May; 12(7):F51-8. PubMed ID: 9619798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 protease inhibitors.
    Deeks SG; Volberding PA
    AIDS Clin Rev; 1997-1998; ():145-85. PubMed ID: 9305448
    [No Abstract]   [Full Text] [Related]  

  • 14. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group.
    Bonfanti P; Valsecchi L; Parazzini F; Carradori S; Pusterla L; Fortuna P; Timillero L; Alessi F; Ghiselli G; Gabbuti A; Di Cintio E; Martinelli C; Faggion I; Landonio S; Quirino T
    J Acquir Immune Defic Syndr; 2000 Mar; 23(3):236-45. PubMed ID: 10839659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health advisory: high blood sugar and diabetes seen in protease inhibitor users.
    Crit Path AIDS Proj; 1997; (No 32):28. PubMed ID: 11364437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials.
    Justesen US; Fox Z; Pedersen C; Cahn P; Gerstoft J; Clumeck N; Losso M; Peters B; Obel N; Castagna A; Dragsted UB; Lundgren JD;
    Basic Clin Pharmacol Toxicol; 2007 Nov; 101(5):339-44. PubMed ID: 17910618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What they say about protease inhibitors.
    Posit Aware; 1999; 10(1):38-43. PubMed ID: 11366522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of HIV protease inhibitors: a survey.
    Ren S; Lien EJ
    Prog Drug Res; 1998; 51():1-31. PubMed ID: 9949858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ritonavir (Norvir) and methadone.
    Treat Rev; 1998; (No 28):15. PubMed ID: 11365421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of saquinavir/ritonavir 1000/100 mg twice daily in patients with tuberculosis receiving rifampin.
    Losso MH; Lourtau LD; Toibaro JJ; Saenz C; González C
    Antivir Ther; 2004 Dec; 9(6):1031-3. PubMed ID: 15651762
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.